Market Overview & Total Size
The global Allergy Care Market—encompassing both diagnostics and therapeutics—was valued at approximately US $31.4 billion in 2022. It is expected to grow to around US $57.9 billion by 2032, at a 6.4 % CAGR from 2023 to 2032 . Meanwhile, segmented intelligence focused solely on allergy therapeutics forecasts a rise from US $22.8 billion in 2024 to US $42.7 billion by 2034, equating to a 7.2 % CAGR . A specific report on "allergy care" projects a growth from US $23.4 billion in 2023 to US $40.5 billion by 2032, yielding a 6.3 % CAGR .
While these figures vary slightly due to differing definitions of allergy segments, collectively the allergy care market—including diagnostics, anti-allergy drugs, immunotherapies, biologics, and digital tools—is projected to expand in the mid-single digits to low double digits annually over the next decade.
Treatment Modalities
1. Anti‑Allergy Drugs (Pharmacotherapy)
This traditional segment remains the largest, driven by widespread accessibility and immediate symptomatic relief. It includes:
Antihistamines, corticosteroids, and decongestants.
In 2022, anti-allergy drugs constituted 84 % of the allergy therapeutics market, with corticosteroids being the largest sub-segment .
The anti‑allergy drug market remains essential due to its affordability, OTC availability, and ease of use—especially for mild to moderate allergy sufferers. However, it lacks the disease-modifying benefits of immunotherapy and biologics.
2. Immunotherapy
A major growth driver, immunotherapy offers long-term control and a potential cure for allergic conditions by desensitizing the immune response. It includes:
Subcutaneous immunotherapy (SCIT) – allergy shots.
Sublingual immunotherapy (SLIT) – tablets or drops.
By 2024, the allergy immunotherapy market (diagnostics aside) stood at between US $1.9 billion and US $3.4 billion, depending on the source . Forecasts to 2032/33 estimate values between US $4.4–7.5 billion, with compound annual growth rates ranging from 8.3–9.8 % .
a) SCIT
Commands around 66 % of the immunotherapy segment by 2023, as it's the longest-established and most clinically validated therapy .
Administered via injections over multiple years, SCIT can achieve durable effects and tolerance development.
b) SLIT – tablets and drops
Tablets currently dominate SLIT delivery, holding over 54 % share .
SLIT offers a patient-friendly alternative to injections, especially with at-home dosing.
Drops are rapidly expanding due to ease of use in infants/children and customizable dosing .
c) Growth dynamics
SLIT is the fastest-growing immunotherapy subtype, driven by convenience and safety .
Tablets retain market share due to established formats, while drops capture increasing share in pediatric and geriatric populations.
3. Biologics & Precision Therapies
Biologic agents—mainly monoclonal antibodies targeting allergic pathways—are emerging as premium therapies for severe allergy cases.
Omalizumab (Xolair): an anti‑IgE monoclonal antibody prescribed for severe allergic asthma, chronic idiopathic urticaria, and food allergy (the latter FDA‑approved in Feb 2024) .
Other biologics target interleukins (e.g., IL‑5, IL‑4Rα) and are approved for asthma and atopic dermatitis (e.g., dupilumab).
Biologics are included under personalized therapies and precision medicine, which are shaping future treatment preferences .
However, due to high costs and need for administration in clinical settings, biologics remain a small but fast-expanding niche.
Market Segmentation by Allergy Type
Different allergic conditions contribute variably to overall market demand:
Allergic rhinitis dominates within immunotherapy, accounting for 71–72 % of that segment in 2024 .
Asthma, notably allergic asthma, is emerging as the fastest-growing allergy type in this market .
Other conditions—such as food allergies, skin allergies (atopic dermatitis, urticaria), and venom allergies—are gaining share via oral immunotherapy and biologics .
Distribution Channels
The modes of allergy care access can be divided into:
Hospital Pharmacies: Historically the main distribution channel for immunotherapy and biologics, holding about 39–40 % share .
Retail Pharmacies: Common for OTC drugs and SLIT tablets.
Online Pharmacies: Fastest-growing channel, offering convenience and home delivery .
Diagnostics tools and at-home test kits are also expanding, supported by telemedicine and digital health integration.
Regional Insights
North America: Leading region with ~39 % market share, driven by strong healthcare systems, reimbursement structures, and biologic adoption .
Europe: Dominated immunotherapy historically (~48 % share in 2024) and SLIT adoption is being pushed via national partnerships .
Asia Pacific: The fastest-growing region (projected 12 % CAGR in immunotherapy), buoyed by rising allergy prevalence, expanding healthcare infrastructure, and rising R&D .
Emerging Markets (Latin America, MEA): Growing awareness, urbanization, and improved diagnosis propelling market uptake.
Drivers & Restraints
✅ Drivers
Rising allergy prevalence due to pollution, urban lifestyles, climate change (~30 % of global population affected) .
Technological innovation: Digital diagnostics, smart inhalers, component-resolved allergen tests .
Personalized medicine: Genetic profiling and precision therapies improving efficacy and compliance .
Regulatory & reimbursement support in North America and Europe, especially for immunotherapy and biologics .
Convenient delivery formats: SLIT tablets/drops + online pharmacies boosting accessibility .
⚠️ Restraints
High treatment costs, particularly immunotherapies and biologics, limiting access in low‑income regions.
Lack of awareness and healthcare infrastructure in developing nations, causing underutilization .
Regulatory complexity, especially for biologics and personalized diagnostics, which slows time to market .
Conclusion
From 2024 to 2032, the allergy care sector is on track for robust expansion:
Anti-allergy drugs remain the volume backbone, catering to symptomatic relief.
Immunotherapy—particularly SLIT tablets and drops—will gain traction for long-term desensitization.
Biologics and personalized medicine will carve out value in specialist treatment segments
By 2032, this evolution will underline a shift from purely symptomatic relief toward curative and precision-driven care—mirroring broader trends in healthcare transformation.
